<DOC>
	<DOCNO>NCT02810275</DOCNO>
	<brief_summary>Patients infected HIV HIV-HCV coinfected high survival due use HAART , survival accompany increased morbidity associate cardiovascular disease ( CVD ) . Endothelial dysfunction early marker atherogenesis , act intermediate causal pathway CVD . Folinic acid ( FA ) show reduce CVD outcome , especially among individual hyperhomocisteinemia . To date , study provide consistent information efficacy pharmacological intervention minimize damage vascular endothelium patient infected HIV HIV-HCV coinfected . The main hypothesis study FA supplementation protect vascular endothelium , consequently might prevent subclinical atherosclerosis . Thus , first step determine efficacy supplementation FA , compare effect HIV HIV-HCV coinfected .</brief_summary>
	<brief_title>Folinic Acid : Supplementation Therapy</brief_title>
	<detailed_description>Study design : This randomize placebo-controlled trial , blind health care team , participant , investigator , participant randomly assign 1:1 ratio receive FA placebo four week . Participants : Patients receive care HIV , outpatient clinic Hospital Universitario de Santa Maria , southern Brazil , October 2012 September 2013 , recruit . Eligible participant : HIV infect HIV-HCV coinfected patient , 18-50 year , men woman , receive HAART , undetectable viral load six month . Patients exclude : patient diabetes mellitus , previous acute myocardial infarction , myocardial revascularization , stroke , creatinine &gt; 1.5 mg/dL , clinical diagnosis ultrasound , endoscopic , laboratory evidence liver cirrhosis , treatment statin , fibrates , hormone replacement therapy , sulfonamide , vitamin supplement , FA last 30 day , pregnant woman . Intervention Patients assign intervention group receive FA 5 mg , per oral , day , morning , four week . Patients assign placebo group receive prescription . The trial provide FA placebo tablet form , identical color , smell , taste , shape , size . Both FA placebo prepare single batch , independent laboratory , pharmacist involvement trial . They pre-packed bottle contain 30 tablet , individually label alphanumeric code store . Outcomes The primary endpoint change homocysteine , vitamin B12 level , brachial artery FMD reactive hyperemia , measure Doppler ultrasound , randomization end follow-up . FMD characterize variation mean arterial flow measure peak change vessel diameter relative baseline . Sample size Sample size calculate base result previous RCT , ( 14 ) use plethysmography measure FMD . To detect difference least 6 % intervention placebo group , standard deviation range 5 % 7 % , calculated sample size least 17 patient per group , randomization stratify HCV coinfection status , require achieve 80 % power 95 % confidence interval .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Inclusion criterion : HIV infect patient HIVHCV coinfected patient 1850 year men woman receive HAART undetectable viral load six month . Patients diabetes mellitus , previous CVD : acute myocardial infarction , myocardial revascularization , stroke , creatinine &gt; 1.5 mg/dL , clinical diagnosis ultrasound , endoscopic , laboratory evidence liver cirrhosis , treatment : statin , fibrates , hormone replacement therapy , sulfonamide , vitamin supplement , FA last 30 day , pregnant woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>